Sarepta Therapeutics(SRPT) - 2023 Q3 - Earnings Call Presentation

BENJAMIN Living with Duchenne muscular dystrophy Other timed secondary endpoints: • Stride velocity 95th centile (SV95C) • 100-meter walk/run (100MWR) • Ascend 4 steps ©SAREPTA THERAPEUTICS, INC. 2023. ALL RIGHTS RESERVED. 5 ©SAREPTA THERAPEUTICS, INC. 2023. ALL RIGHTS RESERVED. 8 NSAA -3.29 (-8.28, 1.70) 0.1942 Overall Treatment Group ELEVIDYS t == Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. ...